ATAI Life Sciences, a German biotech company focused on developing drugs for mental illnesses, has partnered with Neuronasal to develop a short-term treatment for mild traumatic brain injury (mTBI) or concussion. Neuronasal’s concussion treatment includes the intranasal delivery of low doses of N-acetylcysteine (NAC) to patients with acute concussion. N-acetylcysteine has been safely used for […]
Prevacus, a leading US biopharmaceutical company, has announced a strategic partnership with medical device company Blinktbi, utilizing their novel EyeStat device to measure brain function objectively during a Phase 1 clinical trial of a new concussion drug. This collaboration highlights a significant advancement in the treatment and understanding of mild traumatic brain injuries (mTBI) and […]
